

FDA approves cinqair for severe asthma

March 24 2016



(HealthDay)—Cinqair (reslizumab) has been approved by the U.S. Food and Drug Administration to treat severe asthma among adults 18 and older.

Cinqair, given by injection every four weeks, is designed to reduce [severe asthma](#) attacks by reducing blood levels of eosinophils, the FDA said. The drug is to be used in combination with other medications, the agency noted.

In clinical studies involving an unspecified number of severe asthma patients, those who took Cinqair had fewer severe attacks than those who took a placebo, and a longer time to the first attack, the agency said. Users of Cinqair, a lab-developed interleukin-5 antagonist monoclonal antibody, also had improved lung function compared to a placebo.

The FDA warned, however, that Cinqair could cause severe hypersensitivity reactions that could be life threatening.

The drug is produced by Teva Pharmaceuticals, based in Frazer, Penn.

More information: [More Information](#)

[Health News](#) Copyright © 2016 [HealthDay](#). All rights reserved.

Citation: FDA approves cinqair for severe asthma (2016, March 24) retrieved 10 April 2024 from <https://medicalxpress.com/news/2016-03-fda-cinqair-severe-asthma.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
